TransCode Therapeutics, Inc. (RNAZ) earnings

RNAZ earnings moved a median of +0.09% by the close. Quarterly and annual RNAZ reports and results, each read against the price at its own news timestamp. Back to the RNAZ overview →

15 measured RNAZ earnings events.

Where these RNAZ earnings landedvs 15 measured RNAZ earnings reactions
RNAZ earningsMiddle 50% · -6.23% to +6.41%Zero: 0.00%Median: +0.09%Median +0.09%-10.00%0+10.00%
Middle 50% of RNAZ earnings reactions-6.23% to +6.41%
Median reaction (to close)+0.09%
Measured reactions15
Point-in-time · zero look-ahead

Half of the 15 RNAZ earnings events with a measured close landed between -6.23% and +6.41%; 53% closed up.

DateHeadlineEvent5-minTo close
Form 10-Q Transcode Therapeutics, For: Jun 30SEC filing · Form 10-Q-7.49%-5.95%
Form 10-Q Transcode Therapeutics, For: Mar 31SEC filing · Form 10-Q—-6.51%
Form 10-K/A Transcode Therapeutics, For: Dec 31SEC filing · Form 10-K—-4.69%
Form 10-K Transcode Therapeutics, For: Dec 31SEC filing · Form 10-K—-2.03%
Form NT 10-K Transcode Therapeutics, For: Dec 31SEC filing · Form NT—+1.40%
Form 10-Q Transcode Therapeutics, For: Sep 30SEC filing · Form 10-Q+0.00%+4.56%
Form 10-Q Transcode Therapeutics, For: Jun 30SEC filing · Form 10-Q-4.87%-7.78%
Form 10-Q Transcode Therapeutics, For: Mar 31SEC filing · Form 10-Q+0.31%-7.27%
Form 10-K/A Transcode Therapeutics, For: Dec 31SEC filing · Form 10-K+18.25%+17.94%
Form 10-K Transcode Therapeutics, For: Dec 31SEC filing · Form 10-K-4.12%-8.80%
Form NT 10-K Transcode Therapeutics, For: Dec 31SEC filing · Form NT+1.29%+14.16%
Form 10-Q Transcode Therapeutics, For: Sep 30SEC filing · Form 10-Q+3.33%+0.09%
Form 10-Q Transcode Therapeutics, For: Jun 30SEC filing · Form 10-Q+2.21%+8.27%
Form 10-Q Transcode Therapeutics, For: Mar 31SEC filing · Form 10-Q+1.00%+10.60%
Form 10-K Transcode Therapeutics, For: Dec 31SEC filing · Form 10-K+2.65%+1.62%
That’s how RNAZ usually reacts to earnings — get an email when it moves on news →
Keep exploring

More RNAZ: analyst actions → · SEC filings → · RNAZ overview →